Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of arsenic trioxide plus sintilimab in TP53-mutant unresectable advanced intrahepatic cholangiocarcinoma
ChiCTR2300071033Phase 2Not yet recruiting
- Sponsor
- Third Affiliated Hospital of Naval Medical University
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide and sintilimab in intrahepatic cholangiocarcinoma (ICC), sponsored by Third Affiliated Hospital of Naval Medical University. Primary endpoint: Objective response rate. Planned start May 2023; status: not yet recruiting.
02
Drugs
arsenic trioxidesintilimab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on ChiCTR2300071033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071033.